Holen Sie sich die Stockscreener-App
17.82
3.30%
0.57
Handel nachbörslich:
17.95
0.13
+0.73%
Schlusskurs vom Vortag:
$17.25
Offen:
$17.6046
24-Stunden-Volumen:
10,150
Relative Volume:
0.15
Marktkapitalisierung:
$929.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-143.59M
KGV:
-6.3111
EPS:
-2.8236
Netto-Cashflow:
$-119.47M
1W Leistung:
+1.48%
1M Leistung:
+8.07%
6M Leistung:
-3.88%
1J Leistung:
+5.76%
1-Tages-Spanne:
$17.24
$18.10
1-Wochen-Bereich:
$16.72
$18.10
52-Wochen-Spanne:
$11.51
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
Vergleichen Sie PHVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
17.82 | 929.11M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
(PHVS) Trading Advice - news.stocktradersdaily.com
Pharvaris presents new data on oral angioedema treatment at EAACI By Investing.com - Investing.com UK
Clinical Trial Results: Revolutionary Oral HAE Drug Prevents Attacks and Improves Quality of Life in 97.8% of Patients - Stock Titan
Analysts Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20 - Defense World
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim - Defense World
Cantor Fitzgerald Weighs in on Pharvaris FY2026 Earnings - Defense World
Pharvaris (PHVS) Gains Buy Rating with Promising Market Potentia - GuruFocus
Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Guggenheim Initiates Coverage on Pharvaris With Buy Rating, $32 Price Target - marketscreener.com
Pharvaris (PHVS) Receives New Buy Rating and $32 Target from Gug - GuruFocus
Millennium Management LLC Trims Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris Schedules Key Shareholder Meeting: What HAE Treatment Investors Should Know - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
What is Leerink Partnrs’ Forecast for Pharvaris Q2 Earnings? - Defense World
Pharvaris (NASDAQ:PHVS) Given “Outperform” Rating at Wedbush - Defense World
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wed - GuruFocus
Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK
Transcript : Pharvaris N.V.Special Call - marketscreener.com
Pharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock News - GuruFocus
Pharvaris reports promising results for deucrictibant in HAE By Investing.com - Investing.com UK
Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
How To Trade (PHVS) - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World
Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World
Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World
Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World
The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World
Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus
Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus
Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus
Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com
(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan
Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World
When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com
Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World
Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):